These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 8819802)

  • 1. Selective immunomodulation in patients with inflammatory bowel disease--future therapy or reality?
    van Hogezand RA; Verspaget HW
    Neth J Med; 1996 Feb; 48(2):64-7. PubMed ID: 8819802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biologic therapy for inflammatory bowel disease.
    Ardizzone S; Bianchi Porro G
    Drugs; 2005; 65(16):2253-86. PubMed ID: 16266194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Immunopathogenesis of inflammatory bowel diseases].
    Neurath MF; Schürmann G
    Chirurg; 2000 Jan; 71(1):30-40. PubMed ID: 10662999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An immunomodulation strategy targeted towards immunocompetent cells or cytokines in inflammatory bowel diseases (IBD).
    Heresbach D; Sémana G; Gosselin M; Bretagne MG
    Eur Cytokine Netw; 1999 Mar; 10(1):7-15. PubMed ID: 10210767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune system alterations in patients with inflammatory bowel disease during remission.
    Sventoraityte J; Zvirbliene A; Kiudelis G; Zalinkevicius R; Zvirbliene A; Praskevicius A; Kupcinskas L; Tamosiūnas V
    Medicina (Kaunas); 2008; 44(1):27-33. PubMed ID: 18277086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon alpha (IFN alpha 2a) therapy for herpes virus-associated inflammatory bowel disease (ulcerative colitis and Crohn's disease).
    Ruther U; Nunnensiek C; Muller HA; Bader H; May U; Jipp P
    Hepatogastroenterology; 1998; 45(21):691-9. PubMed ID: 9684118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biologic therapies against inflammatory bowel disease: a dysregulated immune system and the cross talk with gastrointestinal mucosa hold the key.
    Dharmani P; Chadee K
    Curr Mol Pharmacol; 2008 Nov; 1(3):195-212. PubMed ID: 20021434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of cytokines in the pathogenesis of inflammatory bowel disease.
    Papadakis KA; Targan SR
    Annu Rev Med; 2000; 51():289-98. PubMed ID: 10774465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5.
    Fuss IJ; Neurath M; Boirivant M; Klein JS; de la Motte C; Strong SA; Fiocchi C; Strober W
    J Immunol; 1996 Aug; 157(3):1261-70. PubMed ID: 8757634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Manipulation of cytokines in the management of patients with inflammatory bowel disease.
    Monteleone G; MacDonald TT
    Ann Med; 2000 Nov; 32(8):552-60. PubMed ID: 11127933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease.
    Reinecker HC; Steffen M; Witthoeft T; Pflueger I; Schreiber S; MacDermott RP; Raedler A
    Clin Exp Immunol; 1993 Oct; 94(1):174-81. PubMed ID: 8403503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy of inflammatory bowel diseases: current concepts and future perspectives.
    Neurath MF
    Arch Immunol Ther Exp (Warsz); 2000; 48(2):81-4. PubMed ID: 10807047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Experimental immunomodulatory therapy of inflammatory bowel disease.
    Schreiber S
    Neth J Med; 1998 Dec; 53(6):S24-31. PubMed ID: 9883011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of interleukin-2-producing intestinal CD4+ T cells in inflammatory bowel disease.
    Kusugami K; Matsuura T; West GA; Youngman KR; Rachmilewitz D; Fiocchi C
    Gastroenterology; 1991 Dec; 101(6):1594-605. PubMed ID: 1683326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative measurement of cytokine mRNA in inflammatory bowel disease: relation to clinical and endoscopic activity and outcome.
    Raddatz D; Bockemühl M; Ramadori G
    Eur J Gastroenterol Hepatol; 2005 May; 17(5):547-57. PubMed ID: 15827446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imbalance of the interleukin 1 system in colonic mucosa--association with intestinal inflammation and interleukin 1 receptor antagonist [corrected] genotype 2.
    Andus T; Daig R; Vogl D; Aschenbrenner E; Lock G; Hollerbach S; Köllinger M; Schölmerich J; Gross V
    Gut; 1997 Nov; 41(5):651-7. PubMed ID: 9414973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patients with inflammatory bowel disease (IBD) reveal increased induction capacity of intracellular interferon-gamma (IFN-gamma) in peripheral CD8+ lymphocytes co-cultured with intestinal epithelial cells.
    Bisping G; Lügering N; Lütke-Brintrup S; Pauels HG; Schürmann G; Domschke W; Kucharzik T
    Clin Exp Immunol; 2001 Jan; 123(1):15-22. PubMed ID: 11167992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transfer of interleukin-4 and interleukin-10 in patients with severe inflammatory bowel disease of the rectum.
    Rogy MA; Beinhauer BG; Reinisch W; Huang L; Pokieser P
    Hum Gene Ther; 2000 Aug; 11(12):1731-41. PubMed ID: 10954907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunological disorders in inflammatory bowel disease and immunotherapeutic implications.
    Amati L; Caradonna L; Jirillo E; Caccavo D
    Ital J Gastroenterol Hepatol; 1999 May; 31(4):313-25. PubMed ID: 10425578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Immunology in medical practice. IV. Inflammatory bowel diseases: pathogenic starting points for specific therapy].
    van Deventer SJ
    Ned Tijdschr Geneeskd; 1997 Oct; 141(41):1956-9. PubMed ID: 9550744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.